First licensed stem cell therapy for ALS
CORESTEM launched the world’s first stem cell therapy for amyotrophic lateral sclerosis in South Korea in 2015. The company is now seeking out-licensing partners as it works toward product approvals in the US and Europe. CORESTEM is a biotechnology company specializing in the research and development of personalized stem cell therapies for neurological and autoimmune diseases. Its lead product is NeuroNata-R (lenzumestrocel), the world’s first stem cell-based therapy for amyotrophic lateral sclerosis (ALS). NeuroNata-R was […]
Phase 3 Trial of Stem Cell Therapy NeuroNata-R Enrolling in Korea
A Phase 3 clinical trial is recruiting adults with amyotrophic lateral sclerosis (ALS) to evaluate the safety and effectiveness of NeuroNata-R (lenzumestrocel), a stem cell therapy approved to treat ALS in South Korea. Enrollment is currently ongoing in South Korea, and patients interested in participating must be able to stay in the country for at least 14 months, Corestem, the therapy’s developer, stated in an email to ALS News Today. ALS is a progressive neurodegenerative disorder caused by the gradual loss of […]